Shiga Toxin–Producing Escherichia coli Transmission
via Fecal Microbiota Transplant
Clinical Infectious Diseases
Our epiXact service for healthcare-associated infections (HAIs) confirmed the first known report of an undetected transmission of Shiga toxin-producing E. coli (STEC) in a fecal microbiota transplantation, despite enzyme-based STEC screening having been performed on donor samples. Following epiXact’s actionable findings, OpenBiome worked, in consultation with the FDA, to implement prospective PCR-based testing to enhance patient safety and avoid future transmissions.
Community-acquired in name only: A cluster of carbapenem-resistant Acinetobacter baumannii in a burn intensive care unit and beyond
Infection Control & Hospital Epidemiology
2020, 1-8. doi.org/10.1017/ice.2020.15
Mass General Hospital used our epiXact service to rapidly identify and respond to a highly-resistant A. baumannii outbreak in an ICU burn unit that was initially believed to be caused by community-transmission.
Plasmids and genes contributing to high-level quinolone resistance in Escherichia coli
International Journal of Antimicrobial Agents
2020 July, Vol 56, Issue 1, 105987.
This research on an E. coli strain with a remarkably high resistance to broad-spectrum antibiotics helps us better understand the transmission of antibiotic resistance between strains via plasmids.
Drug-Resistant E. coli Bacteremia Transmitted by Fecal Microbiota Transplant
The New England Journal of Medicine
Our epiXact service was used by Mass General Hospital to provide high-resolution whole genome sequencing analysis in less than two days to help uncover the cause of the first known fecal matter transplant patient death.
Multiple Copies of qnrA1 on an IncA/C2 Plasmid Explain Enhanced Quinolone Resistance in an Escherichia coli Mutant
Antimicrobial Agents and Chemotherapy
2019 August, Vol. 63, Issue 8.